Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT02871336
Recruiting Observational

Pancreatic Surgical Database

NCT02871336 · tracked via the Priya Life Science France tracker
Sponsor
Institut Paoli-Calmettes
Phase
Observational
Started
2014-11
Last updated
2016-08-18

Condition(s) studied

Pancreatic Neoplasms

Investigational drug(s) / intervention(s)

Data collection

Study summary

This data base has been set in order to gather medical and surgical information from patients who have undergone surgery for pancreatic cancer, at Institut Paoli Calmettes or Assistance Publique des Hôpitaux de Marseille, France.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient \>18 ans * Surgery for a pancreatic cancer Exclusion Criteria: * Patient refusal to participate in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institut Paoli Calmettes Marseille Bouches du Rhone Recruiting

More Institut Paoli-Calmettes trials in France

Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma Recruiting
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Recruiting
Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis Recruiting
Institut Paoli Calmettes Multiple Myeloma Database Recruiting
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation Recruiting

Other trials for the same condition

Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology Recruiting
Institut Paoli-Calmettes Pancreatic Neoplasms Database Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02871336 on ClinicalTrials.gov ↗ ← All trials in France